Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cholangiocarcinoma × Immunotherapy × Clear all

Phase

Status

Unknown 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 2 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Autoimmune Diseases 1

Interventions

Gemcitabine 20 Cisplatin 13 pembrolizumab 5 Fluorouracil 5 pemigatinib 3 Radiotherapy 3 Drug Therapy 3 aldesleukin 2 Radiosurgery 2 Oxaliplatin 2 Nivolumab 2 Liver Transplantation 2 Leucovorin 2 Dexamethasone 2 Cholangiopancreatography, Endoscopic Retrograde 2 Carboplatin 2 Capecitabine 2 trifluridine tipiracil drug combination 1 tremelimumab 1 trametinib 1 spartalizumab 1 seribantumab 1 peginterferon alfa-2b 1 pazopanib 1 padeliporfin 1 ivosidenib 1 irinotecan sucrosofate 1 infigratinib 1 gemcitabine-oxaliplatin regimen 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡